Preclinical trauma studies of recombinant factor VIIa

Martin A. Schreiber, John B. Holcomb, Rasmus Rojkjaer

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Preclinical studies in animals and ex vivo human blood have provided a solid rationale for conducting prospective randomized trials in trauma patients. Small animal models have been utilized to study the efficacy of recombinant activated factor VII (rFVIIa; NovoSeveng®) in treating thrombocytopenic rabbits and for the reversal of anticoagulation. Safety models in the rabbit also exist to test for systemic activation of clotting and pathologic thrombosis. Animal models simulating traumatic injuries in humans have primarily been performed in pigs because of species similarities in terms of coagulation characteristics and the larger internal organs. The pig studies, utilizing human rFVIIa, have shown increased strength of clot formation, decreased bleeding, and improved survival. However, these findings are not uniform and are dependant on the model chosen. All of the animal models described have provided good safety data and suggest that the use of rFVIIa is not associated with systemic activation of coagulation or microthrombosis of end organs.

Original languageEnglish (US)
Pages (from-to)S25-S28
JournalCritical Care
Issue numberSUPPL. 5
StatePublished - Oct 2005

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Preclinical trauma studies of recombinant factor VIIa'. Together they form a unique fingerprint.

Cite this